Rituximab-induced early and late signaling have opposite effects on dexamethasone-induced apoptosis in human follicular lymphoma cells

References

• Dreyling M, Ghielmini M, Marcus R, et al.; ESMO Guidelines Working Group. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011;22(Suppl. 6):vi59–vi63.
   PubMed Web of Science ®Google Scholar
• Sousou T, Friedberg J. Rituximab in indolent lymphomas. Semin Hematol 2010;47:133–142.
   PubMed Web of Science ®Google Scholar
• de Jong D. Molecular pathogenesis of follicular lymphoma: a cross talk of genetic and immunologic factors. J Clin Oncol 2005;23:6358–6363.
   PubMed Web of Science ®Google Scholar
• Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006;25:4798–4811.
   PubMed Web of Science ®Google Scholar
• Marani M, Tenev T, Hancock D, et al. Identification of novel isoforms of the BH3 domain protein Bim which directly activate Bax to trigger apoptosis. Mol Cell Biol 2002;22:3577–3589.
   PubMed Web of Science ®Google Scholar
• Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008;9:47–59.
   PubMed Web of Science ®Google Scholar
• Letai A, Bassik MC, Walensky LD, et al. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2002;2:183–192.
   PubMed Web of Science ®Google Scholar
• Kuwana T, Bouchier-Hayes L, Chipuk JE, et al. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol Cell 2005;17:525–535.
   PubMed Web of Science ®Google Scholar
• Chipuk JE, Moldoveanu T, Llambi F, et al. The BCL-2 family reunion. Mol Cell 2010;37:299–310.
   PubMed Web of Science ®Google Scholar
• Chen L, Willis SN, Wei A, et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 2005;17:393–403.
   PubMed Web of Science ®Google Scholar
• Willis SN, Fletcher JI, Kaufmann T, et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 2007;315:856–859.
   PubMed Web of Science ®Google Scholar
• Uren RT, Dewson G, Chen L, et al. Mitochondrial permeabilization relies on BH3 ligands engaging multiple prosurvival Bcl-2 relatives, not Bak. J Cell Biol 2007;177:277–287.
   PubMed Web of Science ®Google Scholar
• Deng X, Gao F, Flagg T, et al. Mono- and multisite phosphorylation enhances Bcl2’s antiapoptotic function and inhibition of cell cycle entry functions. Proc Natl Acad Sci USA 2004;101:153–158.
   PubMed Web of Science ®Google Scholar
• Breitschopf K, Haendeler J, Malchow P, et al. Posttranslational modification of Bcl-2 facilitates its proteasome-dependent degradation: molecular characterization of the involved signaling pathway. Mol Cell Biol 2000;20:1886–1896.
   PubMed Web of Science ®Google Scholar
• Dimmeler S, Breitschopf K, Haendeler J, et al. Dephosphorylation targets Bcl-2 for ubiquitin-dependent degradation: a link between the apoptosome and the proteasome pathway. J Exp Med 1999;189:1815–1822.
   PubMed Web of Science ®Google Scholar
• Perez-Galan P, Roue G, Lopez-Guerra M, et al. BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells. Leukemia 2008;22:1712–1720.
   PubMed Web of Science ®Google Scholar
• Ito T, Deng X, Carr B, et al. Bcl-2 phosphorylation required for anti-apoptosis function. J Biol Chem 1997;272:11671–11673.
   PubMed Web of Science ®Google Scholar
• Dai H, Ding H, Meng XW, et al. Contribution of Bcl-2 phosphorylation to Bak binding and drug resistance. Cancer Res 2013;73:6998–7008.
   PubMed Web of Science ®Google Scholar
• Lei K, Davis RJ. JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis. Proc Natl Acad Sci USA 2003;100:2432–2437.
   PubMed Web of Science ®Google Scholar
• Luciano F, Jacquel A, Colosetti P, et al. Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. Oncogene 2003;22:6785–6793.
   PubMed Web of Science ®Google Scholar
• Wang J, Zhou JY, Wu GS. Bim protein degradation contributes to cisplatin resistance. J Biol Chem 2011;286:22384–22392.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005;23:5027–5033.
   PubMed Web of Science ®Google Scholar
• Zhang L, Qian Z, Cai Z, et al. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. Am J Hematol 2009;84:553–559.
   PubMed Web of Science ®Google Scholar
• Du J, Wang H, Zhong C, et al. Structural basis for recognition of CD20 by therapeutic antibody rituximab. J Biol Chem 2007;282:15073–15080.
   PubMed Web of Science ®Google Scholar
• Amoroso A, Hafsi S, Militello L, et al. Understanding rituximab function and resistance: implications for tailored therapy. Front Biosci (Landmark Ed) 2011;16:770–782.
   PubMed Web of Science ®Google Scholar
• Manches O, Lui G, Chaperot L, et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 2003;101:949–954.
   PubMed Web of Science ®Google Scholar
• Jazirehi AR, Vega MI, Chatterjee D, et al. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by rituximab. Cancer Res 2004;64:7117–7126.
   PubMed Web of Science ®Google Scholar
• Kheirallah S, Caron P, Gross E, et al. Rituximab inhibits B-cell receptor signaling. Blood 2010;115:985–994.
   PubMed Web of Science ®Google Scholar
• Bonavida B. Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene 2007;26:3629–3636.
   PubMed Web of Science ®Google Scholar
• Eeva J, Nuutinen U, Ropponen A, et al. The involvement of mitochondria and the caspase-9 activation pathway in rituximab-induced apoptosis in FL cells. Apoptosis 2009;14:687–698.
   PubMed Web of Science ®Google Scholar
• Abrams MT, Robertson NM, Yoon K, et al. Inhibition of glucocorticoid-induced apoptosis by targeting the major splice variants of BIM mRNA with small interfering RNA and short hairpin RNA. J Biol Chem 2004;279:55809–55817.
   PubMed Web of Science ®Google Scholar
• Bachmann PS, Gorman R, Mackenzie KL, et al. Dexamethasone resistance in B-cell precursor childhood acute lymphoblastic leukemia occurs downstream of ligand-induced nuclear translocation of the glucocorticoid receptor. Blood 2005;105:2519–2526.
   PubMed Web of Science ®Google Scholar
• Bachmann PS, Gorman R, Papa RA, et al. Divergent mechanisms of glucocorticoid resistance in experimental models of pediatric acute lymphoblastic leukemia. Cancer Res 2007;67:4482–4490.
   PubMed Web of Science ®Google Scholar
• Nuutinen U, Ropponen A, Suoranta S, et al. Dexamethasone-induced apoptosis and up-regulation of Bim is dependent on glycogen synthase kinase-3. Leuk Res 2009;33:1714–1717.
   PubMed Web of Science ®Google Scholar
• Eray M, Postila V, Eeva J, et al. Follicular lymphoma cell lines, an in vitro model for antigenic selection and cytokine-mediated growth regulation of germinal centre B cells. Scand J Immunol 2003;57:545–555.
   PubMed Web of Science ®Google Scholar
• Matto M, Nuutinen UM, Ropponen A, et al. CD45RA and RO isoforms have distinct effects on cytokine- and B-cell-receptor-mediated signalling in human B cells. Scand J Immunol 2005;61:520–528.
   PubMed Web of Science ®Google Scholar
• Nuutinen U, Postila V, Matto M, et al. Inhibition of PI3-kinase-Akt pathway enhances dexamethasone-induced apoptosis in a human follicular lymphoma cell line. Exp Cell Res 2006;312:322–330.
   PubMed Web of Science ®Google Scholar
• Putcha GV, Le S, Frank S, et al. JNK-mediated BIM phosphorylation potentiates BAX-dependent apoptosis. Neuron 2003;38:899–914.
   PubMed Web of Science ®Google Scholar
• Lei K, Davis RJ. JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis. Proc Natl Acad Sci USA 2003;100:2432–2437.
   PubMed Web of Science ®Google Scholar
• Chen D, Zhou Q. Caspase cleavage of BimEL triggers a positive feedback amplification of apoptotic signaling. Proc Natl Acad Sci USA 2004;101:1235–1240.
   PubMed Web of Science ®Google Scholar
• Hubner A, Barrett T, Flavell RA, et al. Multisite phosphorylation regulates Bim stability and apoptotic activity. Mol Cell 2008;30:415–425.
   PubMed Web of Science ®Google Scholar
• Akiyama T, Dass CR, Choong PF. Bim-targeted cancer therapy: a link between drug action and underlying molecular changes. Mol Cancer Ther 2009;8:3173–3180.
   PubMed Web of Science ®Google Scholar
• Fukazawa H, Noguchi K, Masumi A, et al. BimEL is an important determinant for induction of anoikis sensitivity by mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitors. Mol Cancer Ther 2004;3:1281–1288.
   PubMed Web of Science ®Google Scholar
• Ley R, Ewings KE, Hadfield K, et al. Regulatory phosphorylation of Bim: sorting out the ERK from the JNK. Cell Death Differ 2005;12:1008–1014.
   PubMed Web of Science ®Google Scholar
• Hubner A, Barrett T, Flavell RA, et al. Multisite phosphorylation regulates Bim stability and apoptotic activity. Mol Cell 2008;30:415–425.
   PubMed Web of Science ®Google Scholar
• Biswas SC, Greene LA. Nerve growth factor (NGF) down-regulates the Bcl-2 homology 3 (BH3) domain-only protein Bim and suppresses its proapoptotic activity by phosphorylation. J Biol Chem 2002;277:49511–49516.
   PubMed Web of Science ®Google Scholar
• Harada H, Quearry B, Ruiz-Vela A, et al. Survival factor-induced extracellular signal-regulated kinase phosphorylates BIM, inhibiting its association with BAX and proapoptotic activity. Proc Natl Acad Sci USA 2004;101:15313–15317.
   PubMed Web of Science ®Google Scholar
• Paterson A, Mockridge CI, Adams JE, et al. Mechanisms and clinical significance of BIM phosphorylation in chronic lymphocytic leukemia. Blood 2012;119:1726–1736.
   PubMed Web of Science ®Google Scholar
• Ley R, Ewings KE, Hadfield K, et al. Extracellular signal-regulated kinases 1/2 are serum-stimulated “Bim(EL) kinases” that bind to the BH3-only protein Bim(EL) causing its phosphorylation and turnover. J Biol Chem 2004;279:8837–8847.
   PubMed Web of Science ®Google Scholar
• Deng X, Ruvolo P, Carr B, et al. Survival function of ERK1/2 as IL-3-activated, staurosporine-resistant Bcl2 kinases. Proc Natl Acad Sci USA 2000;97:1578–1583.
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Ichijo H, Korsmeyer SJ. BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M. Mol Cell Biol 1999;19:8469–8478.
   PubMed Web of Science ®Google Scholar